Epidemiology of <font color="red">stroke_2</font> <font color="red">._2</font> Importance of preventive pharmacological strategies in <font color="red">elderly_1</font> <font color="red">patients_1</font> <font color="red">and_1</font> <font color="red">associated_2</font> <font color="red">costs_2</font> <font color="red">._2</font> 
<br>
<br> <font color="red">Stroke_1</font> is a major cause of <font color="red">death_1</font> <font color="red">and_1</font> <font color="red">disability_1</font> in developed countries . The incidence of <font color="red">stroke_1</font> increases exponentially with age , yet , traditionally , many medical practitioners have been reluctant to treat <font color="red">hypertension_1</font> in older patients . Since 1991 , the results of 3 major trials -- the <font color="red">British_1</font> <font color="red">Medical_1</font> <font color="red">Research_1</font> <font color="red">Council_1</font> <font color="red">(_1</font> <font color="red">MRC_1</font> <font color="red">)_1</font> <font color="red">trial_1</font> <font color="red">of_1</font> <font color="red">treatment_1</font> <font color="red">in_1</font> <font color="red">older_1</font> <font color="red">adults_1</font> <font color="red">,_1</font> <font color="red">the_1</font> <font color="red">Swedish_1</font> <font color="red">Trial_1</font> <font color="red">in_1</font> <font color="red">Old_1</font> <font color="red">Patients_1</font> <font color="red">with_1</font> <font color="red">Hypertension_2</font> ( <font color="red">STOP_1</font> <font color="red">-_1</font> <font color="red">Hypertension_1</font> <font color="red">)_1</font> <font color="red">and_1</font> <font color="red">the_1</font> <font color="red">Systolic_1</font> <font color="red">Hypertension_1</font> <font color="red">in_1</font> <font color="red">the_1</font> <font color="red">Elderly_1</font> <font color="red">Program_1</font> <font color="red">(_1</font> <font color="red">SHEP)--have_1</font> conclusively established the benefits of treating older patients ( > 60 years ) with both <font color="red">diastolic_1</font> <font color="red">and_1</font> <font color="red">isolated_1</font> <font color="red">systolic_1</font> <font color="red">hypertension_1</font> <font color="red">._1</font> International guidelines for the management of <font color="red">hypertension_1</font> <font color="red">--_1</font> including the Fifth Report of the Joint National Committee , the 1993 report of the World Health Organization and the International Society of <font color="red">Hypertension_1</font> and the second report of the British Hypertension Society Working Party -- have all been modified to reflect the emerging evidence concerning the benefits of treating older patients . <font color="red">Cost_2</font> <font color="red">-_2</font> <font color="red">effectiveness_2</font> <font color="red">data_2</font> are similarly in accord with giving high priority to the treatment of older individuals with <font color="red">hypertension_1</font> <font color="red">._1</font>